drugset / Trial / NCT04426890
To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine Treatment
Timeline
- Start
- 2020-12-09
- Primary completion
- 2022-10-21
- Completion
- 2023-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omalizumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Comparator | Omalizumab | Monoclonal antibody | 300 mg | Subcutaneous |